| symbol |
FCSC |
|---|
| 会社名 | Fibrocell Science Inc （フィブロセル・サイエンス） |
|---|
| 分野（sector） |
Health Care
ヘルスケア
|
|---|
| 産業（industry） |
Major Pharmaceuticals
|
|---|
| 業種 |
バイオテクノロジ―_メディカルリサ―チ
医療関連（Health Care）
|
|---|
| 概要 |
事業概要 Fibrocell Science Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin connective tissue and joints. Its product candidate azficel-T is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate FCX-007 is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate FCX-013 is in pre-clinical development for the treatment of linear scleroderma. Its product LAVIV (azficel-T) is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product LAVIV (azficel-T) is focused on improving the appearance of nasolabial fold wrinkles in adults. フィブロセル・サイエンスは、米国のバイオテクノロジ―会社。皮膚の疾患向け治療法の開発を目指す。独自の繊維芽細胞技術に基づいて、コラ―ゲンを生産する繊維芽細胞を増殖して肌に戻すことで、老化、太陽光、にきび、日焼けによるダメ―ジを治療する。また、同社の臨床開発プログラムは、制限的な火傷、声帯瘢痕と遺伝的変異の治療を目指す。 Fibrocell Science, Inc. is an autologous cell and gene therapy company, which focuses on translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. The company was founded on December 28, 1995 and is headquartered in Exton, PA.
|
|---|
| 本社所在地 | 405 Eagleview Boulevard Exton PA 19341 USA |
|---|
| 代表者氏名 | Douglas J. Swirsky ダグラスJ.スワルキー |
|---|
| 代表者役職名 | Chairman of the Board 取締役会会長 |
|---|
| 電話番号 | +1 484-713-6000 |
|---|
| 設立年月日 | 1995年 |
|---|
| 市場名 | NASDAQ Small Cap |
|---|
| ipoyear | ―年 |
|---|
| 従業員数 | 52人 |
|---|
| url | www.fibrocellscience.com |
|---|
| nasdaq_url | https://www.nasdaq.com/symbol/fcsc |
|---|
| adr_tso | ― |
|---|
| EBITDA | EBITDA（百万ドル） -15.15600 |
|---|
| 終値（lastsale） | 2.19 |
|---|
| 時価総額（marketcap） | 20399810.58 |
|---|
| 時価総額 | 時価総額（百万ドル） 19.84091 |
|---|
| 売上高 | 売上高（百万ドル） 0.00000 |
|---|
| 企業価値(EV) | 企業価値(EV)（百万ドル） 4.43091 |
|---|
| 当期純利益 | 当期純利益（百万ドル） -3.81500 |
|---|
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Fibrocell Science Inc revenues was not reported. Net loss applicable to common stockholders decreased 73% to $6.2M. Lower net loss reflects Warrant revaluation income (expense) increase from $9.7M (expense) to $326K (income) Other income (expense) net increase from $6K to $98K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$7.82 to -$1.03. |
|---|
FCSC - フィブロセル・サイエンス （Fibrocell Science Inc.） フィブロセル・サイエンス